Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial.

"Disclosure The authors report no conflicts of interest in this work."

"This study was supported by the National Key Clinical Specialty Construction Project in 2021 (3030294001): Construction of a multidisciplinary treatment team for the Department of Allergy and Immunology at Huashan Hospital."

"A prospective, single-center, randomized, controlled trial comparing hydrogen therapy and NAC in patients with early-stage ILD. Patients were recruited from January 1, 2019, to December 31, 2021, in the Department of Dermatology and Department of Allergy & Immunology, Huashan Hospital Affiliated to Fudan University in Shanghai, China. The trial was approved by the local ethics committee and was registered as ChiCTR-ONC-17013055. Informed consent was obtained from all recruited patients in accordance with the Declaration of Helsinki. Ethics Approval and Informed Consent: The trial was approved by the Ethics Committee of Huashan Hospital affiliated with Fudan University and registered as ChiCTR-ONC-17013055. Informed consent was obtained from all the recruited patients in accordance with the Declaration of Helsinki (revised in 2013)."